Clinical Trials Logo

Malignant Solid Tumor clinical trials

View clinical trials related to Malignant Solid Tumor.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05539157 Active, not recruiting - Clinical trials for Malignant Solid Tumor

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Start date: October 18, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors

NCT ID: NCT05103358 Active, not recruiting - Cancer Clinical Trials

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Start date: February 15, 2022
Phase: Phase 2
Study type: Interventional

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

NCT ID: NCT03834662 Active, not recruiting - Clinical trials for Malignant Solid Tumor

A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies

Start date: January 7, 2019
Phase: Phase 1
Study type: Interventional

TGFβ has profound local immunosuppressive and immunoexclusion effects in the tumor microenvironment that are integrally involved in the failure of immune checkpoint inhibitors in some tumors. Preclinical data in a variety of models strongly support the study of AVID200 in patients with treatment-refractory advanced and metastatic malignancies as an approach to reducing immunosuppression/exclusion and increasing the activity of immune checkpoint inhibitors.

NCT ID: NCT03694249 Active, not recruiting - Clinical trials for Malignant Solid Tumor

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

Start date: December 12, 2018
Phase: Phase 2
Study type: Interventional

This pilot trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment and spreading throughout the body. Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.

NCT ID: NCT02999750 Active, not recruiting - Clinical trials for Malignant Solid Tumor

EXtendedAnalysis for Cancer Treatment

Start date: October 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to prospectively validate treatment benefit of an individualized treatment concept based on molecular profiling (MP) from paraffin-embedded tumor tissue sections obtained before the start of treatment (real time biopsy).